| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/4/21 A | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +1.68% | +2.13% | +16.17% | +77.49% | 48.36B | |
| +1.52% | +2.95% | +60.39% | +112.28% | 35.8B | |
| -0.09% | -0.66% | -8.03% | +31.90% | 11.83B | |
| -0.05% | -3.10% | +13.50% | +77.95% | 11.48B | |
| +0.56% | -0.37% | +37.53% | +142.08% | 9.01B | |
| +0.18% | +0.58% | +49.62% | -9.13% | 6.99B | |
| +0.95% | -1.59% | +12.34% | +32.81% | 6.7B | |
| +0.18% | -1.77% | +2.36% | +172.36% | 6.42B | |
| +3.51% | -10.57% | -31.55% | +0.09% | 5.3B | |
| Average | +1.56% | -1.21% | +16.93% | +70.87% | 15.77B | |
| Weighted average by Cap. | +1.18% | -0.14% | +25.51% | +81.63% |
Employees
2,191
Sector
Pharmaceuticals
